Two 2 billion products in hand, three chemical drugs in East China Pharmaceutical 1.1 in research projects

In recent days, Huadong pharmaceutical has released the latest performance In 2017, its operating revenue reached 27.832 billion yuan, an increase of 9.66% over the previous year The net profit attributable to shareholders of the parent company was 1.78 billion yuan, an increase of 23.01% over the previous year Among them, the commercial sales revenue exceeded 20 billion yuan, and the pharmaceutical business sales revenue exceeded 6.6 billion yuan At present, Huadong pharmaceutical has 7 products with sales scale of more than 100 million yuan, including two heavy-duty products of 2 billion yuan In addition, how are the three chemical 1.1 projects currently under development in Huadong Pharmaceutical Co., Ltd.? None = "shifumousedownstyle ('shifu bus')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino Sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line height: 25.6px; width: 1; Border style: none solid; text align: Center; border bottom width: 1px; border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> China, the United States and East China: revenue and net profit growth exceeding 20% figure 1: revenue of East China medicine from 2014 to 2017 (unit: 100 million yuan) (data source: annual report of listed companies) In 2017, the commercial sales revenue of East China medicine exceeded 20 billion yuan, and kept the industry leading in Zhejiang Province Huadong pharmaceutical mentioned in the annual report that the growth rate of the company's operating revenue decreased year on year, mainly due to the formal implementation of the two vote system in Zhejiang Province in November 2017, and the centralized loss of the transfer business in commercial distribution in the fourth quarter of 2017 due to the impact of the policy Since 2018, the impact will be basically eliminated In the future, the company will focus on the pure sales business and the general agent and general distribution business of products, strive to restore to the original growth level and continue to expand the share of the pharmaceutical distribution market in the province The core wholly-owned subsidiary of the company's pharmaceutical industry, China, the United States and East China, achieved an operating revenue of 6.613 billion yuan and a net profit of 1.336 billion yuan, up 21.72% and 21.57% respectively from the same period last year At present, China, the United States and East China have formed a stable product echelon in the four product areas of chronic kidney disease, transplantation immunity, endocrine, digestive system, etc., and the four product lines have maintained a good growth in 2017   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> according to the annual report data of two 2 billion yuan heavyweight products, there are many products with outstanding sales achievements in the four major product areas of China, the United States and East China At present, there are seven products with sales scale of more than 100 million yuan, including two 2 billion yuan heavyweight products Bailing Capsule and acarbose tablet (trade name: carbepin) Figure 2: Sales of Bailing Capsule in China's public medical institutions in 2013-2016 (unit: 10000 yuan) (data source: minernet China's public medical institutions terminal competition pattern) Bailing capsule is the exclusive product of China, the United States and East China It has the functions of nourishing lung and kidney, benefiting essence and Qi It is used for the auxiliary treatment of cough, asthma, hemoptysis, lumbago and backache, chronic bronchitis and chronic renal insufficiency caused by deficiency of lung and kidney The main market of this product is in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public hospitals Medical institution) From 2014 to 2016, bailing capsule ranked the top 20 in the terminal products of traditional Chinese medicine, waist strengthening and kidney strengthening medicine (nephrology medicine) of public medical institutions in China, and its sales in the terminal of retail pharmacies in China also exceeded 200 million yuan In the market, bailing related products also include tablets Currently, bailing tablets produced by Qinghai Everest Cordyceps sinensis Pharmaceutical Co., Ltd are active in the market In 2016, the sales of this product in the terminals of public medical institutions in China exceeded 100 million yuan According to the annual report data, in 2017, several key R & D projects of East China Pharmaceutical Co., Ltd have been progressing smoothly, and the production approval of Bailing tablet has been obtained At present, the production document number of the product is being transferred from the New Drug Research Institute of East China Pharmaceutical Group It is expected that the product will not only enrich the product line of Huadong pharmaceutical bailing series, but also further stimulate the company's performance Figure 3: Sales of Acarbose Tablets in China, the United States and East China at the terminals of public medical institutions in 2013-2016 (unit: 10000 yuan) (data source: minenet China public medical institutions terminal competition pattern) Acarbose Tablets are used to treat diabetes and reduce postprandial blood sugar of people with low glucose tolerance In the past four years, this product has ranked first among the top 20 end-user chemical diabetes drug products of public medical institutions and top 20 end-user chemical diabetes drug products of urban retail pharmacies in China The main sales market of Acarbose Tablets is in the terminals of public medical institutions in China In 2016, the sales volume exceeded 5 billion yuan, while the sales volume of retail drugstores in cities in China was about 1.3 billion yuan In the market, the competitors of Acarbose Tablets are Bayer and Central America and East China At the end of China's public medical institutions, Bayer's market share fell from 80.15% in 2013 to 68.56% in 2016, while China, the United States and East China continued to eat the market, from less than 20% in 2013 to 31.44% in 2016 In 2016, in China's urban retail drugstore terminals, the market share of China, the United States and East China was 27.09%, and the sales volume was 356 million yuan   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the 3 chemical pharmaceutical 1.1 research projects are worth looking forward to In 2017, the total direct and indirect spending on R & D of East China Pharmaceutical and major industrial holding subsidiaries was about 462 million yuan, an increase of 74.84% over the previous year, accounting for 6.95% of the company's pharmaceutical manufacturing business revenue In 2018, the company will accelerate the progress of new product research and development, and it is expected that the expenditure of research and development expenses in 2018 will increase by more than 30% The new drug R & D of East China Pharmaceutical is combined with "independent development + cooperative commissioned development + external acquisition and product license in" In 2017, the company has obtained a large number of clinical approval to enter the clinical research of new products Due to the significant increase in the volume of new drug policy be samples, the company also pays attention to the implementation of consistency evaluation and the application of multiple products for international registration develop Table 1: progress of class 1.1 research projects of Huadong Pharmaceutical (data source: annual report of listed companies) shows that there are currently 33 major research projects in Huadong pharmaceutical, including 3 in chemical 1.1, 4 in chemical 3.1 and 2 in chemical 3.2 On December 21, 2017, China, the United States and East China signed an agreement with vtv company of the United States to obtain and commercialize the intellectual property rights of ttp273, a product for the treatment of type 2 diabetes, including but not limited to technology development, clinical research, application for regulatory approval, patent or trademark registration, production and all commercialization in the region The project is currently in the stage of technology transfer and preclinical research in China Hd118, a new DPP-4 class I new drug for the treatment of type 2 diabetes, obtained the clinical approval at the end of 2017 The preparation of clinical samples is in progress and clinical trials will be carried out soon Mehuatinib, a new drug for advanced non-small cell lung cancer, has completed phase I clinical trial and is carrying out three phase II clinical scheme designs, including first-line, second / third-line and above third-line It is expected to carry out a large-scale multi center clinical trial in 2018 Chemical medicine 3.1 projects include the treatment of lymphoma with irutinib and capsule, the treatment of leukemia with bosudinib and tablets, the treatment of gastric ulcer with zopantoprazole sodium and injection, vonolazan and tablets At present, four projects have obtained clinical approval, preparation of clinical samples and clinical trials Chemical medicine 3.2 projects include compound tablets of carboglizine and metformin for the treatment of type 2 diabetes mellitus At present, clinical approval has been obtained, clinical samples have been prepared, and clinical trials have begun; there are compound omeprazole sodium bicarbonate capsules for the treatment of gastric ulcer, which have been declared for production by the end of 2017 Several other research projects of the company have also made some progress Dabawanxin and its freeze-dried powder injection, pioglitazone metformin compound tablets with new specifications (15 / 850mg) have obtained clinical approval, and clinical trials will be carried out; kapofungin and micafungin are carrying out hair tonic research; xigliptin metformin compound tablets The company has completed the be filing, carried out the formal be test, and is expected to apply for production in 2018; the company has also carried out the preparation of clinical samples for several projects, such as tragliptin tablets, linezolid tablets, anastrozole tablets, letrozole tablets, tacrolimus sustained-release capsules, and kaglitazine tablets, all of which are in the pre be or formal be stage In addition, the company has completed the clinical approval for the transfer of new drugs for lilalutide injection, a key product of diabetes, from Hangzhou Jiuyuan Genetic Engineering Co., Ltd., and has started the first phase of clinical pharmacokinetic research; ditirin has completed the pre clinical trial, applied for clinical application and received acceptance; and is carrying out the slimming indication of lilalutide transferred from Hangzhou Jiuyuan Genetic Engineering Co., Ltd In 2017, the company has submitted a document number transfer application to CFDA for acceptance of the new Chinese medicine Ruanjian oral liquid (used for auxiliary treatment of liver cancer) purchased from outside, which is currently under technical review by the drug review center   none="shifuMouseDown('shifu_t_002')" style="margin: 1em auto; padding: 0.5em 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border: none; text-align: center; width: 670px; box-sizing: border-box !im portant; Word wrap: break word! Im assistant; "> conclusion Huadong pharmaceutical said that through the joint efforts of all employees in 2017, it successfully completed the annual production and operation objectives, achieved the double harvest of reform and development, and maintained a steady and rapid development for 18 consecutive years since the company went public In the future, East China Pharmaceutical will continue to advance towards the "two 10 billion" dream of East China By 2020, the industrial sales of China, the United States and East China will reach 10 billion yuan, and by 2025, the sales of "bailing + carbopin based diabetes series products" will reach 10 billion yuan; the sales of pharmaceutical business will reach 30 billion yuan in 2020, and by 2025, the sales will reach 50 billion yuan, and the profits will strive to reach 1 billion yuan; besides Hangzhou, Commercial business has an average market share of more than 25% in all cities of the province Source: minernet database, annual report of listed companies